Archive

Hits: 1259
Bìol. Tvarin, 2018, volume 20, issue 1, pp. 116–122

STUDY OF STABILITY OF EXPERIMENTAL LIVING VACCINE AGAINST ANIMAL ANTHRAX WITH STRАIN UA–07 “ANTRAVAK” (18 MONTHS AFTER PRODUCTION)

I. A. Rublenko1, V. G. Skripnik2
This email address is being protected from spambots. You need JavaScript enabled to view it.

1Bila Tserkva National Agrarian University,
126 Stavischanska str., Bila Tserkva 09117, Ukraine

2Ukrainian Association of Manufacturers and Distributors
of Veterinary Preparations and Feed Additives,
16 Vasylkivska str, Kyiv 03040, Ukraine

For the prevention of anthrax, various vaccines are developed. The article presents the results of investigations on determination of the experimental live vaccine stability against anthrax from animals of the genus Bacillus anthracis UA–07 “Antravak”.
Experimental vaccines of series 1 and 2 were studied according to the following indices: appearance, presence of foreign impurities, mass fraction of glycerin, pH, amount of live spores, mass spores, contamination, growth pattern, homogeneity, morphology, mobility, capsule formation, harmlessness, residual virulence, immunogenicity activity, storage temperature.
The stability of the studied parameters of the vaccine series 1 and 2 during the study period (6, 12 and 18 months after the making) was established. In the study the mass fraction of glycerin was revealed 29–31%, pH was within 7,5–7,7, the amount of live spores in 1 cm3 was found within 13,48–14,23 million; the vaccine did not cause swelling, skin necrosis, animal death, it was immunogenic for 90 %.
In the study of the parameters of the vaccine series 2, the absence of foreign impurities, bacterial and fungal microflora was revealed.
According to the results of the research, it was found that the experimental vaccine against anthrax from Bacillus anthracis UA–07 “Antravak” strain of series 1 and 2, regardless of storage temperature, was almost constant in the study.

Keywords: ANTHRAX, VACCINE, ANTRAVAC, BACILLUS ANTHRACIS, NECESSITY, SPORI, IMMUNOGENICITY, TEMPERATURE, UNIFORMITY, STABILITY

  1. Berger T., Kassirer M., Aran A.A. Injectional anthrax — new presentation of an old disease. European communicable disease bulletin, 2014, vol. 19, no. 32. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25139073.
  2. Centers for Disease Control and Prevention. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001.Morb Mortal Wkly Rep., 2001, no. 50, рр. 889–893.
  3. Centers for Disease Control and Prevention. Human anthrax associated with an epizootic among livestock North Dakota, 2000. Morb. Mortal Wkly. Rep., 2001, no.50, рp. 677–680. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5032a1.htm.
  4. Cote C. K., Kaatz L., Reinhardt J. Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as to xaemia. Journal of Medical Microbiology, 2012, no. 61, рр. 1380–1392. https://doi.org/10.1099/jmm.0.045393-0
  5. Gerberding J. L., Hughes J. M., Koplan J. P. Bioterrorism preparedness and response: clinicians and public health agencies as essential partners.JAMA, 2002, no. 287, рр.898–900.
  6. Inglesby T. V., Henderson D. A., Bartlett J. G., Ascher M. S., Eitzen E., Friedlander A. M. Anthrax as a biological weapon: medical and public health management. JAMA, 1999, no. 281, рр. 1735–1745.
  7. Inglesby T. V, O’Toole T., Henderson D. A., Bartlett J. G., Ascher M. S., Eitzen E. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA, 2002, no. 287, рр. 2236–2252.
  8. Laws T. R., Kuchuloria T., Chitadze N. A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines. PLOS ONE, 2016, vol. 11, no. 3: e0148713. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805272. https://doi.org/10.1371/journal.pone.0148713
  9. OvsyannikovaI. G., Pankratz V. S., Vierkant R. A. Human Leukocyte Antigens and Cellular Immune Responses to Anthrax Vaccine Adsorbed. Infect Immun., 2013, vol. 81, no. 7, рр. 2584–2591. https://doi.org/10.1128/IAI.00269-13
  10. Rublenko I. O., Skrypnyk V. G. Analysis of the data of epizootic outbreaks of anthrax on the territory of Ukraine (1994–2016). Scientific Herald of Veterinary Medicine, Bila Tserkva National Agrarian University, 2016, vol. 1, no. 127. pp. 87–95. (in Ukrainian)
  11. Webb G. F., Blaser M. J. Mailborne transmission of anthrax: modeling and implications. Proc. Natl. Acad. Sci. USA, 2002, no. 99, рр. 7027–7032.

Download full text in PDF

gslogoICLOGO

cr

nbuv

WorldCat Logo

oa

Search